Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs ALLEGRA ALLERGY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (pruritus and hives)
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Fexofenadine 180 mg orally once daily.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life is 14.4 hours (range 8–16 hours) in healthy adults. In renal impairment, half-life may be prolonged; dose adjustment recommended for Cr Cl <30 m L/min.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Fexofenadine undergoes minimal hepatic metabolism; approximately 5% of the dose is metabolized by CYP3A4. It is primarily excreted unchanged in feces and urine.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Primarily eliminated in feces (80%) and urine (approximately 15%) as unchanged drug. Biliary secretion contributes significantly.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
60-70% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Steady-state volume of distribution (Vdss) is 5.4–16 L/kg (mean ~12 L/kg). The large Vd indicates extensive tissue distribution.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Oral bioavailability is approximately 30% (range 25–40%) due to first-pass metabolism. Bioavailability is reduced by fruit juices (e.g., grapefruit, apple, orange).
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
GFR 40-59 m L/min: 60 mg once daily; GFR 15-39 m L/min: 60 mg every other day; GFR <15 m L/min: not recommended.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe (Child-Pugh C).
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Children 2-11 years: 30 mg orally twice daily; Children 12 years and older: same as adult dosing.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No specific dose adjustment, but elderly patients may be more sensitive to anticholinergic effects; consider starting at lower end of dosing range. No renal adjustment needed if renal function normal.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
None.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Use with caution in patients with renal impairment (Cr Cl < 80 m L/min) as exposure is increased; consider dose adjustment.,Avoid concurrent use with aluminum- and magnesium-containing antacids, which reduce fexofenadine absorption by up to 40%.,Potential for QT prolongation at high doses (rare); caution in patients with pre-existing QT prolongation or electrolyte imbalances.,Not recommended for severe hepatic impairment due to lack of data.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to fexofenadine or any component of the formulation,End-stage renal disease (ESRD) with Cr Cl < 15 m L/min (use not recommended)
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Fruit juices (apple, orange, grapefruit) significantly decrease absorption of fexofenadine; avoid concurrent consumption. No other significant food interactions.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate, well-controlled studies in pregnant women. First trimester: Limited data suggest no increased risk of major malformations. Second and third trimesters: No known specific fetal risks from antihistamine use; however, use only if clearly needed due to lack of extensive human data.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.24. Based on limited data, the relative infant dose is estimated to be less than 5% of the maternal weight-adjusted dose, which is considered low. However, caution is advised due to potential effects on the infant, such as drowsiness or irritability. Use only if clearly needed, and monitor the infant for adverse effects.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
No specific dosing adjustments are recommended for fexofenadine during pregnancy, as pharmacokinetic data are limited. However, due to physiological changes in pregnancy (e.g., increased plasma volume, renal clearance), the standard adult dose (60 mg twice daily or 180 mg once daily) may require cautious use; consider lowest effective dose. No formal studies have been conducted to determine dose modifications.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Fexofenadine is a second-generation antihistamine with minimal CNS penetration, causing less sedation than first-generation agents. Onset of action is within 1 hour; peak effect at 2-3 hours. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to reduced clearance. Antacids containing aluminum or magnesium reduce absorption; separate by at least 2 hours. No significant QT prolongation at therapeutic doses.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Take with water; do not take with fruit juices (apple, orange, grapefruit) as they reduce absorption.,Do not use with antacids containing aluminum or magnesium; wait at least 2 hours between doses.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not exceed recommended dose; overdose may cause dizziness, drowsiness, or dry mouth.,Store at room temperature away from moisture and heat.,Consult healthcare provider if symptoms persist >7 days or if fever occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs ALLEGRA ALLERGY, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. ALLEGRA ALLERGY is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and ALLEGRA ALLERGY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of ALLEGRA ALLERGY is: Fexofenadine 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and ALLEGRA ALLERGY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. ALLEGRA ALLERGY is classified as Category C. Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.